BioSpace News Archive

Arimoclomol will be reviewed under Priority Review with a PDUFA date of March 17, 2021. Here’s more about it.

Paradigm4, specialist in scientific data management and scalable computation, has launched its REVEAL: Single CellTM app to offer biopharmaceutical developers the ability to break through the data wrangling and programming challenges associated with the analysis of large-scale, single-cell datasets.

Ashion Analytics GEMExTra test detects rare NRG1 gene fusions in patients whose cancer is driven by this genomic alteration for potential matching to a clinical trial [16-September-2020] PHOENIX , Sept. 16, 2020 /PRNewswire/ -- Ashion Analytics LLC today announced a partnership with Elevation Oncology , a clinical stage biopharmaceutical company, focused on the m

With genetic testing on the rise and the science advancing, there is an increased demand for board-certified genetic counselors who can interpret findings and advise both patients and providers.

- Forty students received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvement/extracurricular activities - The public is now invited to cast their votes to help determine this year’s Thriving Scholars - Scholarships totaling $25,000 each - the Thriving Undergraduate Scholarship and the Thriving Graduate Scholarship - will be awarded to two deserving students

National Ultrasound has signed an exclusive distribution agreement for the United States with Elesta.

The GMTO Corporation has received a $17.5 million grant from the National Science Foundation (NSF) to accelerate the prototyping and testing of some of the most powerful optical and infrared technologies ever engineered.

The sixth PCORI Annual Meeting — one of the most inclusive and diverse annual gatherings of representatives from the entire spectrum of health care decision makers and stakeholders — kicks off today with a stimulating opening keynote on flattening hierarchies and blurring the lines between “researchers” and “patients” in the clinical research enterprise.

The National Organization for Rare Disorders (NORD®) has announced the second annual Rare Cancer Day, taking place September 30, 2020 . Spearheaded by the NORD Rare Cancer Coalition, which is composed of

Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022 2020 Half-year results and business update TG4001: Very promising results from Phase 1b/2 trial in HPV-positive cancers TG6002: Initial translational results confirm the value of intravenous administration Preclinical and clinical projects progressing despite the Covid-19 pandemic €33.2 million of cash at the end of June 2020 wa